Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine September 2018, 59 (9) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

Oligometastatic prostate cancer: Jadvar provides an overview of this complex disease setting and recommends increased research and analytic foci on precise and optimal molecular imaging and clinical management techniques.

Page 1338

Imaging cancer metabolism: Pantel and colleagues discuss the underlying biology of metabolic dysregulation in cancer, including glucose, glutamine, and acetate metabolism and associated imaging strategies.

Page 1340

Covalent labels for PET: Pichler and colleagues offer an educational overview of the radiochemistry of PET tracers that exhibit a covalently bound radiolabel with 11C, 13N, and 18F, including the tracer life cycle from radionuclide production through quality control.

Page 1350

PET metallomics: Bartnicka and Blower report on the growing availability of positron-emitting isotopes of key essential metals, particularly 64Cu, 63Zn, and 52Mn, that provide new tools with which to image disturbed metal homeostasis.

Page 1355

SUV and tumor progression: Cornelis and colleagues investigate whether intraprocedural 18F-FDG PET/CT can serve as a biomarker and predictor of local tumor progression after percutaneous ablation of colorectal liver metastases.

Page 1360

SPECT/CT for lung shunt quantification: Dittmann and colleagues evaluate quantitative SPECT/CT for hepatopulmonary fraction assessment in a prospective clinical cohort scheduled to undergo selective internal radiotherapy for liver metastases.

Page 1366

99mTc-PSMA vs 99mTc-MDP: Rathke and colleagues assess the rates of detection of bone metastases with these 2 tracers in patients with known advanced-stage osseous metastasized prostate cancer.

Page 1373

18F-Fludarabine for lymphoma imaging: Chantepie and colleagues describe a first-in-humans clinical study of 18F-fludarabine PET in patients with diffuse large B-cell lymphoma or chronic lymphocytic leukemia.

Page 1380

HER2-selective tyrosine kinase inhibitor: Tang and colleagues detail the development of a 125/131I-labeled agent targeting human epidermal growth factor receptor type 2 and evaluate it in HER2-positive and -negative subcutaneous human breast cancer xenografts.

Page 1386

68Ga-PSMA11 PET/CT in mice: Lückerath and colleagues explore the reproducibility of imaging signal and relationship between quantitative cell-surface prostate-specific membrane antigen expression and prostate cancer lesion detectability with this tracer in small animal PET/CT.

Page 1392

Immuno-PET/NIRF in pancreatic cancer: Zettlitz and colleagues develop a dual-labeled probe based on A2 cys-diabody targeting of the cell-surface prostate stem cell antigen, with potential for both whole-body PET in pancreatic cancer and near-infrared fluorescence surgical guidance.

Page 1398

PSMA ligand uptake in ganglia: Rischpler and colleagues explore physiologic prostate-specific membrane antigen ligand uptake on 68Ga-PSMA-HBED-CC PET in cervical, celiac, and sacral ganglia of the sympathetic trunk as a confounding factor in imaging lymph node metastases in prostate cancer.

Page 1406

Fibroblast-activating protein: Siveke offers perspective on the potential for therapeutic targeting of cancer-associated fibroblasts, a multifunctional and abundant cell population in tumor microenvironments, and previews 2 associated articles in this issue of JNM.

Page 1412

Theranostic ligands for FAP: Lindner and colleagues research in preclinical studies and in preliminary human testing a radiolabeled fibroblast activation protein inhibitor with promise for imaging and targeted therapy of tumors with high activated fibroblast content, such as breast cancer.

Page 1415

Imaging of activated fibroblasts: Loktev and colleagues describe an iodinated and a DOTA-coupled radiotracer based on a fibroblast activation protein–specific enzyme inhibitor and evaluate them in vitro and in tumor-bearing animals.

Page 1423

Myocardial perfusion in Chagas disease: Oliveira and colleagues investigate the occurrence of myocardial perfusion defects and correlated regional changes to histology in an experimental hamster model of chronic Chagas cardiomyopathy.

Page 1430

Metabolic pattern of iRBD: Meles and colleagues identify the 18F-FDG PET metabolic pattern underlying idiopathic rapid eye movement sleep behavior disorder and compare it with the known Parkinson disease pattern.

Page 1437

Age and 5-HT6 receptors in men: Radhakrishnan and colleagues explore in healthy men the effects of age on 5-HT6 receptor availability using 11C-GSK215083, a PET ligand with affinity for 5-HT6 in the striatum and 5-HT2A in the cortex.

Page 1445

Fetal dosimetry in PET/CT: Xie and colleagues expand on previously developed computational phantoms for pregnant women and describe a personalized model for patient-specific radiation dose in a twin pregnancy.

Page 1451

Imaging bystander payload distribution: Cilliers and Thurber offer perspective on antibody–drug conjugates, a promising class of therapeutics for molecular targeting, and preview an article in this JNM issue on dual-isotope tracking of both antibody and payload with these conjugates.

Page 1459

CIQA for ADC intratumoral distribution: Ilovich and colleagues present a dual-isotope cryoimaging quantitative autoradiography methodology combined with 3D imaging and analysis for simultaneous study of both antibody and payload distribution of antibody–drug conjugates in tissue.

Page 1461

Impact of PET/MR motion correction: Manber and colleagues test the ability of a PET/MR-based predictive model to correct PET respiratory motion and determine whether it can improve lesion detectability and quantitation and reduce image artifacts.

Page 1467

PET/DCE-MR concurrent motion correction: Fuin and colleagues detail an approach for concurrent reconstruction of respiratory motion–compensated abdominal dynamic contrast-enhanced MR and PET imaging data in an integrated PET/MR scanner.

Page 1474

PET/CT respiratory motion correction: Lu and colleagues establish a framework to address artifacts from mismatches between respiration-gated PET images and CT attenuation correction maps, as well as other limitations of current respiratory motion correction methods.

Page 1480

  • © 2018 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 59 (9)
Journal of Nuclear Medicine
Vol. 59, Issue 9
September 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Sep 2018, 59 (9) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Sep 2018, 59 (9) 8A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • Immediate Postablation 18F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases
  • Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
  • Dual-Isotope Cryoimaging Quantitative Autoradiography: Investigating Antibody–Drug Conjugate Distribution and Payload Delivery Through Imaging
  • Patient-Specific Computational Model and Dosimetry Calculations for PET/CT of a Patient Pregnant with Twins
  • 68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging
  • Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET
  • A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
  • An Overview of PET Radiochemistry, Part 1: The Covalent Labels 18F, 11C, and 13N
  • A Prospective Study of Quantitative SPECT/CT for Evaluation of Lung Shunt Fraction Before SIRT of Liver Tumors
  • Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
  • Insights into Trace Metal Metabolism in Health and Disease from PET: “PET Metallomics”
  • Clinical Impact of Respiratory Motion Correction in Simultaneous PET/MR, Using a Joint PET/MR Predictive Motion Model
  • Imaging Cancer Metabolism: Underlying Biology and Emerging Strategies
  • Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti–Prostate Stem Cell Antigen Cys-Diabody
  • Concurrent Respiratory Motion Correction of Abdominal PET and Dynamic Contrast-Enhanced–MRI Using a Compressed Sensing Approach
  • The Metabolic Pattern of Idiopathic REM Sleep Behavior Disorder Reflects Early-Stage Parkinson Disease
  • Regional Myocardial Perfusion Disturbance in Experimental Chronic Chagas Cardiomyopathy
  • Fibroblast-Activating Protein: Targeting the Roots of the Tumor Microenvironment
  • “Standing by” for Bystander Effects: Dual-Isotope Imaging of Antibody–Drug Conjugate and Payload Distribution
  • Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging
  • Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer
  • Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology
  • Respiratory Motion Compensation for PET/CT with Motion Information Derived from Matched Attenuation-Corrected Gated PET Data
  • 18F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire